Investing News Network on MSN
Moderna to pay US$950 million to settle COVID-19 vaccine patent dispute
Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used ...
Arbutus Biopharma (ABUS) lost ~14% in the premarket on Friday after the company disclosed that the Board of Appeal of the European Patent Office revoked one of its patents, which was the subject of a ...
Two stocks are standing out in premarket trading this Wednesday morning. Moderna (Nasdaq: MRNA) is up 8.9% and Ross Stores (Nasdaq: ROSS) is up 6.6% as of 8:00 AM ET, each moving on a distinct ...
A patent dispute over technology key to messenger RNA Covid-19 vaccines is settling with Moderna agreeing to pay $950 million up front and potentially more than $1 billion later, a resolution that ...
Moderna MRNA announced that it entered a settlement agreement resolving a patent dispute with Genevant Sciences, a subsidiary of Roivant Sciences ROIV, and Arbutus Biopharma ABUS. With this deal, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results